MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financi...( Those investments are starting to show ...),Health
Navigation Links
MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
Date:2/28/2008
"Those investments are starting to show results, as we recently initiated a Phase 3 clinical trial of UDB in children with asthma, and reached agreement with the FDA on a special protocol assessment for a Phase 3 clinical trial of MAP0004 in patients with migraine."
Fourth Quarter and 2007 Year End Financial Results
Research and development expenses for the fourth quarter and year ended December 31, 2007 were $13.0 million and $31.4 million, respectively, compared to $7.2 million and $22.3 million, respectively, for the same periods in 2006. The increase in research and development expenses for the fourth quarter of 2007 was primarily related to increases in clinical trial expenses and personnel expenses to support the company's growth in preparation for its Phase 3 clinical programs related to its two lead product candidates. The increase in research and development expenses for the year ended 2007 was primarily related to increases in clinical trial expenses and personnel expenses to support the company's growth in preparation for its Phase 3 clinical programs related to its two lead product candidates, partially offset by a decrease in milestone expenses predominantly related to its two lead product candidates.
Sales, general and administrative expenses for the fourth quarter and year ended December 31, 2007 were $2.7 million and $9.6 million, respectively, compared to $1.3 million and $4.1 million, respectively, for the same periods in 2006. The increase in sales, general and administrative expenses for the fourth quarter of 2007 and year ended 2007 was primarily related to increases in personnel expenses, professional services related to becoming a public company, professional services for marketing activities and share-based compensation.
MAP Pharmaceuticals had cash, cash equivalents and short-term
investments as of December 31, 2007 of $95.0 million, compared to $17.7
million as of December 31, 2006. The increase was due primarily
'/>"/>
| SOURCE MAP Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
(Date:12/4/2009)... , WASHINGTON, Dec. 4 /PRNewswire-USNewswire/... for the Aging (AAHSA) applauds the Senate for ens...rvices (CLASS) provisions remain in the final heal...ssential for providing support to elders, people w...rge the Senate to pass a health care reform bill t...
(Date:12/4/2009)... , WASHINGTON, Dec. 4 /PRNewswire-USNewswi...reform would control health care costs, Leapfrog,s... through example -- delivering the best quality ca...s of efficiency. Thirty-four urban, eight children...Leapfrog Top Hospitals, based on results from The ...
(Date:12/4/2009)...ase Western Reserve University researchers, from t...iscovered two new metabolic pathways by which prod..., known as 4-hydroxyacids, are metabolized. The pa...omics and mass isotopomer analysis. The findings s...ug of abuse gamma-hydroxybutyrate, also known as "...
(Date:12/4/2009)...reasing exercise, water and fruit consumption lea... Dec. 4 (HealthDay News) -- Increased exercise, re... the most effective weight control strategies for ...urveyed 130 adolescents about their weight-control...cceeded in losing weight and 68 had not. The respo...
(Date:12/4/2009)...ther the H1N1 virus will come back during winter i...4 (HealthDay News) -- The number of states reporti...ine this week -- to 25 from a high of 48 just two ..., Meanwhile, the supply of H1N1 swine flu vaccine ...ctor of the U.S. Centers for Disease Control and P...
Breaking Medicine News(10 mins):Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:Swine Flu Continues to Wane 2[0] Statement from AAHSA CEO Larry Minnix on the Failure of the Thune Amendment[0] The Leapfrog Group Releases Its 2009 Top Hospitals List[0] Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week'[0] Teens Lose More Weight Using Healthy Strategies[0] Swine Flu Continues to Wane
...AD, Inc. (Nasdaq:,ICAD), an industry-leading provi...r the early identification of cancer, today announ...utive with the private equity,firm, Welsh, Carson,...he number of directors to eight. Mr. Ecock, age,46...
...rship with New President, Congress on,Public-Priva...Health Care,Payment Systems to Emphasize Wellness,...ition of chief,executives from many of the nation,... health care gap, between the status,quo and the ,...
...y 200] Scientists at the Swedish medical universit... shown that a receptor called ALK7 plays important... well as the release of insulin from beta-cells in...at removing the ALK7 receptor improves insulin rel...
...wareness Releases its 2007 Claims Review from,Lead...stration Data,, PORTLAND, Maine, May 13 Data fro...leased today by the Council for,Disability Awarene...th long-term disabilities has grown four times,the...
...inhua-PRNewswire-FirstCall/ -- China Sky One,Medic...) (OTC Bulletin,Board: CSKI), a leading fully inte...er-the-counter drugs in the People,s Republic of C...the Waldorf Astoria in New York City., Mr. Yanqin...
...8) -- Promising results from a team of NewYork-Pre...ysician-scientists show that gene therapy is both ...atten disease, or Late Infantile Neuronal Ceroid L...cal trial found that the procedure -- which involv...
Other Medicine News:Health News:iCAD, Inc. Appoints Anthony F. Ecock to Board of Directors 2Health News:CEOs From Multiple Health Industries Announce Consensus Plan to Reform U.S. Health Care 2Health News:CEOs From Multiple Health Industries Announce Consensus Plan to Reform U.S. Health Care 3Health News:Novel mechanisms controlling insulin release and fat deposition discovered 2Health News:New Data Shows Continued Growth of Long-Term Disability Claims and Decline in Social Security Disability Insurance Applications Approval Rate 2Health News:New Data Shows Continued Growth of Long-Term Disability Claims and Decline in Social Security Disability Insurance Applications Approval Rate 3Health News:China Sky One Medical, Inc. to Present at Brean Murray Carret & Co. All-Cap All-China Conference 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2iCAD, Inc. Appoints Anthony F. Ecock to Board of DirectorsCEOs From Multiple Health Industries Announce Consensus Plan to Reform U.S. Health CareNovel mechanisms controlling insulin release and fat deposition discoveredNew Data Shows Continued Growth of Long-Term Disability Claims and Decline in Social Security Disability Insurance Applications Approval RateChina Sky One Medical, Inc. to Present at Brean Murray Carret & Co. All-Cap All-China ConferenceNYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease
(Date:12/4/2009)..., Workers Ensure Emergency Deliveries are Tran...SNewswire/ -- Teamster members employed by the Phi...rd at work educating the public about the unfair l...ially put Philadelphia,s blood supply at risk. Mo...picket line yesterday when their issues were ignor...
(Date:12/4/2009)..., STREAMWOOD, Ill., Dec. 4 Shar...I and PET/CT systems and service programs for hosp...unce it has received The Joint Commission,s Accred...ecognized, prestigious gold seal of approval for q...accreditation is system-wide for its mobile MRI an...
(Date:12/4/2009)..., ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ ...nse company developing medical countermeasures aga...day that the Company is presenting results of a st...74; in an inhalation anthrax model in the New Zeal...ted during an oral session at the HHS Public Healt...
Breaking Medicine Technology:Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6FDA Clears Caspofungin 28Cancidas 28R 29 29 Susceptibility Testing for TREK Sensititre 28R 29 YeastOne 28R 29 in Vitro Diagnostics 28IVD 29 Product 12925 1FDA Clears Caspofungin 28Cancidas 28R 29 29 Susceptibility Testing for TREK Sensititre 28R 29 YeastOne 28R 29 in Vitro Diagnostics 28IVD 29 Product 12925 2FDA Clears Caspofungin 28Cancidas 28R 29 29 Susceptibility Testing for TREK Sensititre 28R 29 YeastOne 28R 29 in Vitro Diagnostics 28IVD 29 Product 12925 3NIH Stem Cell Guidelines Ethically Irresponsible Scientifically Unworthy Useless to Patients Says Family Research Council 50952 1NIH Stem Cell Guidelines Ethically Irresponsible Scientifically Unworthy Useless to Patients Says Family Research Council 50952 2Press Ganey Announces Opening of Boston Office 50948 1Press Ganey Announces Opening of Boston Office 50948 2...SAN DIEGO, March 12 ADVENTRX Pharmaceuticals,Inc....ta from the Company,s,Phase 2 clinical study of AN...breast cancer has been accepted for presentation a...ASCO) Annual Meeting, which takes,place May 30 - J...ion entitled "5,10 methylenetetrahydrofolic acid,w...
...Committee Recommends FDA Approve Novel Anesthesia ...ation within Minutes, KENILWORTH, N.J., March 11 ...t the U.S. Food and Drug Administration,(FDA) Advi... recommended,sugammadex for approval. After review...ion, the committee unanimously recommended approva...
Other Medicine Technology:ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) 2ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) 3FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 2FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 3FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |